Latest News

24 May 2023

Case Study Reveals Potentially Lethal Side Effects of Lecanemab for Treatment of Alzheimer's Disease

In a noteworthy case study published in the Journal of Alzheimer’s Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer’s disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab. Four days after the last infusion, she experienced stroke symptoms and died several days later due to multifocal intracerebral hemorrhage despite attempts at therapeutic intervention. Neuropathologic findings reflected therapy-induced Aβ phagocytosis involving fibrillar Aβ both in the parenchymal brain tissue and in the cerebral vasculature.

4 April 2023

Depression and the Absence of a Stable Partner Can Accelerate Alzheimer’s Disease in People with Genetic Risk

Neurosciences Group of the University of Antioquia (GNA), Colombia

Depressive symptoms and the absence of a stable partner can accelerate the progression of Alzheimer's disease in people who carry a genetic mutation. In addition, adequate treatment and controls in people with thyroid problems help delay depressive symptoms, progression to dementia, and death. These findings were reached by a team of researchers from the Universidad de Antioquia, Colombia, Universidad Nacional de Colombia, and Hamburg-Eppendorf University Medical Center, Germany, in a population with the "paisa mutation" or presenilin 1, E280A mutation carriers, for early-onset Alzheimer's disease.

9 March 2023

Researchers from Rowan University and Durin Technologies announce highly accurate blood test for Alzheimer’s Disease

A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer’s disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate. Their findings appear online ahead of press in the Journal of Alzheimer’s Disease.

9 March 2023

New Cleveland Clinic-Developed Screening Tool Can Assess Cognition Issues in Older Adults

Cleveland Clinic

A self-administered screening tool, developed by Cleveland Clinic researchers, can effectively and efficiently assess cognition issues in older adults. A new study found that the simple test taken on a tablet computer before an annual physical is conducive to use in a primary care setting for detecting mild cognitive impairment, early Alzheimer’s disease, and other related dementias. Results were published in Journal of Alzheimer’s Disease.

6 February 2023

Do Sleep Medications Increase Your Chances of Dementia?

UCSF Health

A new study shows that sleep medications increase the risk of dementia in whites. But the type and quantity of the medication may be factors in explaining the higher risk. It follows previous work that shows Blacks have a higher likelihood than whites of developing Alzheimer’s, the most common type of dementia, and that they have different risk factors and disease manifestation.

6 February 2023

Study finds obesity-related neurodegeneration mimics Alzheimer’s disease

Thinning in the right temporo-parietal cortex and left prefrontal cortex were similar in both groups

A new study led by scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University finds a correlation between neurodegeneration in obese people and Alzheimer’s disease (AD) patients. Previous research has shown that obesity is linked with Alzheimer’s disease (AD)-related changes, such as cerebrovascular damage and amyloid-β accumulation. However, to date no research has made a direct comparison between brain atrophy patterns in AD and obesity.

24 January 2023

Exposure to World Trade Center Dust Exacerbates Cognitive Impairment in an Animal Model of Alzheimer’s

Mount Sinai Logo

Mice exposed to World Trade Center dust exhibit a significant impairment in spatial recognition and short- and long-term memory, as well as changes in genes related to immune-inflammatory responses and blood-brain barrier disruption, according to a study conducted by researchers from the Icahn School of Medicine at Mount Sinai and published January 17 in the Journal of Alzheimer’s Disease.


Subscribe to Latest News